Sage Therapeutics, Inc.
https://www.sagerx.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sage Therapeutics, Inc.
Biogen Asks For Yet More Patience As Leqembi Sales Begin Slow Ascent
CEO Chris Viehbacher outlined progress Biogen made in the third quarter, including full approval for the Eisai-partnered Alzheimer’s drug Leqembi, but recent wins will take time to make up for long-term revenue declines.
Sage Readies Zurzuvae For December Launch With Slow Ramp As Payer Talks Progress
Sage and Biogen set a $15,900 list price for Zurzuvae, the 14-day postpartum depression drug approved in the US in August, and expect broad access but formulary discussions will continue into 2024.
Breakdowns In The Breakthrough Lane: When Recipients Of FDA Expedited Designation Fall Short
Safety signals were the most common cause of discontinued candidates in the breakthrough therapy designation program in 2023.
Sage Details 40% Job Cuts While Zurzuvae’s Future In MDD Remains Unclear
Zurzuvae will launch this year for postpartum depression, but US FDA rejection of the drug in major depressive disorder spurred Sage to cut R&D programs and jobs as it and partner Biogen evaluate next steps in MDD.
Company Information
- Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- ADMET
-
Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice